Regulators in the USA have given the green light to Johnson & Johnson's new diabetes combo Invokamet.

The US Food and Drug Administration has approved Invokamet, a fixed-dose therapy combining Invokana (canagliflozin) and metformin. The former, a member of the new class of drugs known as sodium glucose co-transporter 2 (SGLT2) inhibitors, was approved in the USA as a single agent in March last year.

The thumbs-up is based on Phase III studies which showed that the combo lowered blood sugar and reduced secondary endpoints of body weight and systolic blood pressure to a greater degree than metformin alone. Invokamet is the first fixed–dose combination of an SGLT2 inhibitor with metformin to be approved in the USA and is available at two doses (50mg/500mg or 150mg/1000 mg, to be taken twice daily.

Canagliflozin works with the kidney to promote the loss of glucose in the urine, whereas metformin decreases the production of glucose in the liver and improves the body's response to insulin.

For more details, go to: http://www.pharmatimes.com/Article/14-08-10/FDA_approves_J_J_diabetes_drug_Invokamet.aspx